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taurolidine, and silver ions have been updated. For critically 
colonized and infected chronic wounds as well as for burns, 
polihexanide is classified as the active agent of choice. The 
combination 0.1% OCT/phenoxyethanol (PE) solution is suit-
able for acute, contaminated, and traumatic wounds, includ-
ing MRSA-colonized wounds due to its deep action. For 
chronic wounds, preparations with 0.05% OCT are prefera-
ble. For bite, stab/puncture, and gunshot wounds, polyvinyl-
pyrrolidone (PVP)-iodine is the first choice, while poli-
hexanide and hypochlorite are superior to PVP-iodine for the 
treatment of contaminated acute and chronic wounds. For 
the decolonization of wounds colonized or infected with 
MDROs, the combination of OCT/PE is preferred. For perito-
neal rinsing or rinsing of other cavities with a lack of drainage 
potential as well as the risk of central nervous system expo-
sure, hypochlorite is the superior active agent. Silver-sulfadi-
azine is classified as dispensable, while dyes, organic mer-
cury compounds, and hydrogen peroxide alone are classi-
fied as obsolete. As promising prospects, acetic acid, the 
combination of negative pressure wound therapy with the 
instillation of antiseptics (NPWTi), and cold atmospheric 
plasma are also subjects of this assessment. 
 © 2017 S. Karger AG, Basel 
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 Abstract 
 Wound antisepsis has undergone a renaissance due to the 
introduction of highly effective wound-compatible antimi-
crobial agents and the spread of multidrug-resistant organ-
isms (MDROs). However, a strict indication must be set for 
the application of these agents. An infected or critically colo-
nized wound must be treated antiseptically. In addition, sys-
temic antibiotic therapy is required in case the infection 
spreads. If applied preventively, the Wounds-at-Risk Score 
allows an assessment of the risk for infection and thus ap-
propriateness of the indication. The content of this updated 
consensus recommendation still largely consists of discuss-
ing properties of octenidine dihydrochloride (OCT), poli-
hexanide, and iodophores. The evaluations of hypochlorite, 
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 Renaissance of Xenobiotic Wound Antiseptics 
 Wound antiseptics lost some of their importance for 
more than a century due to the toxicity of Lister’s carbolic 
wound spray, the toxic side effects of the next generation of 
antiseptics such as mercury- or arsenic-based compounds, 
and the initial euphoria after the introduction of the antibi-
otic penicillin G. Reasons for the renaissance of antiseptics 
are the development of effective and well-tolerated antisep-
tic substances, the pandemic spread of multidrug resistant 
organisms (MDROs), a comparatively high rate of sensiti-
zation to locally applied antibiotics, the microbicidal in-
stead of microbiostatic effect of antiseptics, the locally de-
limited effect with no or – in the case of polyvinylpyrrol-
idone-iodine (PVP-I) – few systemic consequences when 
correctly applied considering contraindications, and last 
but not least, the absence of resistance development for 
those antiseptic agents which damage pathogens irrevers-
ibly. For example, so far, no resistance has been observed 
against antiseptics with unspecific effects, such as the de-
struction of the bacterial cell as a whole, or the inhibition of 
its function with destruction of the cell membrane or block-
age of negative surface charges. This is the case for octeni-
dine dihydrochloride (OCT), polihexanide (PHMB), PVP-
I, and oxidizing agents, such as hypochlorous acid, or active 
substances from the class of peroxides/peroxy acids, such as 
hydrogen peroxide (H 2 O 2 ). Microbiostatic antiseptics, how-
ever, show transferable resistances, and can be partially 
cross-resistant with certain antibiotics. Examples are the ac-
tivation of efflux pumps  [1, 2] for chlorhexidine digluconate 
(CHD) and quaternary ammonium compounds, and a ge-
netically coded periplasmatic Ag(I)-binding protein and 2 
efflux pumps for silver ions  [3] . This is also true for topi-
cally applied antibiotics such as mupirocin  [4] , silver sulfa-
diazine  [5–7] , neomycin, and bacitracin  [8] , which have all 
lost their significance as wound antiseptics, except for mu-
pirocin  [9] , which is still used for the decolonization of 
MRSA (methicillin-resistant  Staphylococcus aureus ). Espe-
cially the over-the-counter sale (without prescription) of 
mupirocin as a wound antiseptic is considered to be a major 
cause for the increase in resistance development  [5, 10] , 
which can locally exceed more than 20% of examined hos-
pital-associated MRSA strains  [11] .
 The local application of antibiotics for locally confined wound 
infections and colonization is to be avoided, not only because of 
the promotion of resistance development, but also because of 
their microbiostatic mode of action and concentrations that are 
hard to adjust. Any systemic escalation of the infection, such as 
positive blood cultures, must be treated with systemic antibiotics 
in combination with topic antiseptics, if necessary. 
 Since the microbicidal effect of antibiotics can only be 
examined in a suspension test and has thus seldom been the 
focus of studies, only a few published reports on minimal 
inhibitory concentration (MIC) exist which could serve as 
a basis for comparison. Nevertheless, this literature shows 
that many antiseptics are vastly more effective compared to 
antibiotics ( Table  1 ). For gentamicin, which is also ap-
proved for topical use as a cream, the MIC for sensitive  S. 
aureus was 0.5–1 μg/mL, for  Pseudomonas aeruginosa 2 μg/
mL  [12] , and for Enterobacteriaceae 25–75 μg/mL  [13] . In 
contrast, for fluoroquinolones for example, the MIC against 
sensitive  Escherichia coli is 0.008–0.02 μg/mL, which is 
much lower than for OCT or PHMB, where the MIC may 
be up to 1,000 μg/mL for resistant strains  [14] . The use of 
this antibiotic would not be recommendable. 
 The German Society for Wound Healing and Wound 
Treatment (Deutsche Gesellschaft für Wundheilung und 
Wundbehandlung) only recommends microbiological 
diagnostics for chronic wounds if there are signs of a sys-
temic infectious event originating from the wound area 
 [15] . For this reason, the local application of antibiotics 
used for the treatment of systemic infections should be 
avoided in order to circumvent the development of resis-
tance and sensitization  [16] . The WHO also does not rec-
ommend topical use of or rinsing with antibiotics in this 
case  [17] ( Table 1 ).
 Evidence Regarding Wound Antiseptics 
 An infected or critically colonized wound must be microbio-
logically remediated in order to heal properly  [18–20] . It must be 
determined whether the topical use of antiseptics is sufficient or 
if a systemic antibiosis is necessary due to septic spreading. If a 
wound is at risk of becoming infected, antiseptics can prevent the 
emergence of infection  [21] .
 Table 1.  MIC (μg/mL) at 24 h exposure of selected antibiotics and 
antiseptics against microbial test strains
Microbial strain Cefuroxime 
[269, 270]
OCT [50] PHMB [50]
S. aureus 0.5 to 64 2 0.5
MRSA 16 1 0.5
E. faecalis 2 to 128 1 2
VRE – 4 4
E. coli 8 to >400 8 0.5
P. aeruginosa >400 8 2
C. albicans – 1 1
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 Although the proper treatment of wounds has been a 
challenge since the beginning of mankind, sufficient evi-
dence is lacking for the choice of antiseptics to prevent 
wound infections as well as treat wounds, especially 
chronic ones. Many dermatological patients suffer from 
different types of erosive skin lesions, e.g., follicular bac-
terial infections  [22, 23] or eczema  [24] . Often, local an-
tibiotics are used instead of considering antiseptic op-
tions for treatment, although according to expert opin-
ion, the latter are more effective and do not pose a risk of 
resistance development  [22] . This leads to the conclusion 
that further studies and observations must be undertaken 
to examine the potential of antiseptic treatment for these 
conditions. Since only a small number of clinical trials are 
available as the basis for decisions, all available results 
from studies ranging from in vitro experiments up to 
clinical studies, including meta-analyses, must be collect-
ed to form a plausible synopsis  [18] . For this reason, all 
clinical studies available in PubMed were taken into ac-
count for Tables 6–9, regardless of the evidence level. 
 Classification of Compounds for Wound Antisepsis 
 Products declared as wound antiseptics are classified 
as pharmacological drugs (PDs). If the mechanical effects 
such as rinsing (solutions) or absorption (gauzes) are the 
primary mode of action and the antiseptic effect is only 
provided by the addition of preservatives, the product is 
classified as a medical device (MD). The distinction from 
PDs is based on the primary mode of action and the in-
tention for use as described by the manufacturer. PDs act 
pharmacologically, metabolically, and/or immunologi-
cally, while MDs primarily act physically. The pharmaco-
logical mode of action can take various manifestations: 
 – The binding to adhesion proteins or their biochemical 
or immunological destruction can inhibit or prevent 
the attachment of bacteria  [25, 26] . As long as patho-
gens residing and multiplying in the upper cell layers 
are killed, the effect is considered pharmacological, 
since reproduction cannot take place without adhe-
sion on receptors and interaction with the tissue.  
 – Wound healing can be supported by biochemical 
means, such as interaction with inflammation media-
tors. This was observed for PVP-I  [27] , OCT  [28] , and 
hypochlorous acid  [29] .  
 – Healing can also be supported for aseptic wounds. 
This was observed for liposomal PVP-I  [30] and 
PHMB  [31, 32] , although the exact mechanism has yet 
to be explained. 
 It is always considered to be a pharmacological mode 
of action if wound healing is supported by the antiseptic 
effects on cell-adherent pathogens, possibly with associ-
ated biochemical or immunological consecutive reac-
tions. This is also true if the active substance binds to the 
wound tissue and offers a so-called remanent effect by 
gradual release  [33, 34] . If the main mode of action of 
wound rinsing solutions or wound dressings is based on 
physical means, e.g., rinsing, absorption, moisture regu-
lation, or irreversible physicochemical binding of micro-
organisms, they are classified as MDs. In practice, the 
transition between MPs and MDs is fluid, since physical 
and pharmacological modes of actions cannot be strictly 
separated. Since the classification does bear consequenc-
es for pharmacological-toxicological and clinical testing 
as well as user protection, the correct classification is im-
portant in terms of ethics and reimbursement. This de-
marcation is further complicated by the approval of some 
antiseptics such as PHMB as a preservative in antisepti-
cally effective concentrations and their use in wound 
treatment preparations without further declaration  [33, 
34] . Because of this, all comparisons made within this 
consensus recommendation require further careful eval-
uation and interpretation. 
 Indications 
 The use of antiseptics for prophylactic or therapeutic indica-
tions in wound treatment is possible for the following objectives:
 – Prevention of infection of acute wounds, e.g., after trauma, 
bite, or gunshot wounds 
 – Prevention of postsurgical wound infections (surgical site in-
fections; SSI) 
 – Decolonization of wounds colonized with MDRO  
 – Treatment of clinically manifested wound infections, includ-
ing so-called critical colonization 
 – Preparation for debridement or wound cleaning of chronic 
wounds in outpatient facilities 
 The interaction between microorganisms and wounds 
can take place on different levels ( Table 2 ). The clinically 
characterized term “critical colonization” reflects the 
hard to define condition of the transition between physi-
ological wound colonization and the pathological condi-
tion of a manifest local infection  [35] .
 Although almost all wounds, especially chronic ones, 
are contaminated, not all patients develop an infection. 
Since physiological colonization is either irrelevant or – 
due to colonization resistance – even beneficial for the 
process of wound healing  [36] , the Wounds-at-Risk 
(WAR) Score  [37] , which is the sum of different points, 
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was introduced in order to evaluate the infection risk 
( Table 3 ).
 If the WAR Score reaches or exceeds 3 points, an antiseptic 
treatment is justified.
 Criteria for Choosing Antiseptic Agents 
 Efficacy 
 When treating acute wounds, a microbicidal effect and 
broad spectrum of activity are desirable. Only in certain 
cases does the substance have to be virucidal and addi-
tionally effective against bacterial spores. For chronic 
wounds, the spectrum of activity must only encompass 
Gram-positive and Gram-negative bacteria if no special 
circumstances have been diagnosed. There should be no 
risk for the development of resistance, especially cross-
resistance towards antibiotics.
 The efficacy of antiseptics is expected to result in killing of test 
organisms ≥3 log 10  [38, 39] for a typical type of organic load 
within the declared exposure time. 
 In some cases, the efficacy is additionally tested without 
an organic load typical for wounds, although this does not 
correspond to the application situation, unless the load is 
significantly reduced, for example by repeated rinsing. With-
out an organic load, the efficacy is expected to be ≥5 log 10 
versus bacteria and ≥4 log 10 versus  Candida  albicans  [38] .
 Tolerability 
 The tolerability of antiseptics in wounds is supposed to be 
equal to Ringer solution, physiological saline, or an inert hydro-
gel. Ideally, wound healing is promoted. 
 A good point of orientation would be to follow the prac-
tical approach of not applying anything to chronic wounds 
which should not be applied to the eyes. This is true for 
PVP-I up to 5% and for PHMB up to 0.02%  [40–42] , but 
not for silver sulfadiazine, CHD, or OCT (0.1%). If adja-
cent tissues can be exposed in the wound treatment, such 
as cartilage, central nervous system (CNS), or peritoneum, 
the compatibility must be clarified. Furthermore, sensiti-
zation potential including anaphylaxis risk should be low 
or absent; there should also be no risk of long-term adverse 
effects such as mutagenicity, carcinogenicity, or teratoge-
nicity. If the quotient of bactericidal efficacy and tolerabil-
ity against mouse fibroblasts in vitro, both tested under the 
same conditions, is >1, the tolerance for the antiseptic of 
eukaryotic cells is better than that of bacteria. This is true 
for OCT, PHMB, and almost for PVP-I ( Table 4 ). A de-
tailed observation about the selective antiseptic effect can 
be made when, in cocultures of human cells and bacteria, 
the prokaryotic cells are destroyed, while the eukaryotic 
cells survive, or bacteria in a comparable solution are killed 
without damage to human cells. This is demonstrated for 
sodium hypochlorite (NaOCl)  [43] , PHMB  [44] , and PVP-
I  [45] . Analogously, the treatment of epidermis equivalents 
 Table 2.  Classification of the microbial status of wounds
Term Characteristics
Contamination Microorganisms are present and have attached to the tissue (microbial attachment)
without (initial) proliferation
Colonization Microorganisms are present and are proliferating; a clinically significant 
immunological host reaction is (initially) absent
Critical colonization Microbial proliferation without the formation of classical signs of infection but 
delayed wound healing due to toxin production/or the wound is colonized with 
antibiotic resistant strains without signs and symptoms of infection
Local infection Clinically observable, immunological host reaction with the typical signs of infection 
including redness (erythema 1 – 2 cm measured from the wound margin) with 
tendencies of increase could be equivalent to spreading infection with the risk of 
generalization, swelling, increased local skin/tissue temperature, pain, functional 
impairment, and increase in exudate quantity and viscosity, for example, perceptible 
odor and stagnation in wound healing
Systemic infection In addition to the local inflammatory reactions, signs of a systemic host reaction
such as leukocytosis, increase in C-reactive protein and fever
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derived from human keratinocytes with OCT alone or in 
combination with test organisms demonstrated no cyto-
toxic effect in viable keratinocytes  [51] . In contrast, H 2 O 2 
inhibits mammalian cells beginning with a concentration 
of 8.5 mg/L [46], thus inhibiting fibroblasts, whereas bac-
teria still survive  [47] . However, this is not transferable to 
the endogenous formation of H 2 O 2 occurring in the con-
text of the nonspecific immune response, for example by 
granulocytes. Thus, 0.003% H 2 O 2 already inhibits the cy-
tolytic activity of natural killer cells, but the killer cells re-
main vital  [48] . Even if, for example, H 2 O 2 is formed in 
noncytotoxic concentrations in medical honey by glucose 
oxidase, this is not comparable with the external antiseptic 
application of pure H 2 O 2 alone  [49] .
 In acute wounds the fast-acting effect of the antiseptic is at the 
forefront, under certain circumstances with a necessary depth ef-
fect, for example in patients with bite, puncture, or gunshot injuries. 
For chronic wounds, a longer exposure time is acceptable for reach-
ing the antiseptic effect due to repeated application and/or remain-
ing on the wound. Wound healing should also be promoted here.
 Taking into account the different properties of anti-
septic active ingredients ( Table 5 ), the following develop-
ment trends are apparent. PVP-I has partly lost impor-
tance due to the introduction of more recent and ad-
vanced substances. By solving the stability problem, the 
combination of sodium hypochlorite/hypochlorous acid 
 Table 3.  Assessment of risk for wound infection [37]
Risk class Risk condition (based on risk status and different indications) Point score
1 Acquired immunosuppressive disease (e.g., diabetes mellitus)
Acquired immune defect due to medical therapy such as cyclosporine, 
methotrexate, glucocorticoids, or antibodies
Solid tumor disease
Systemic hematological disease
Postsurgical wound healing disorder, which results in (unplanned) secondary 
healing
Potentially heavily contaminated wounds (e.g., perineum, genitals)
Problematic hygienic conditions related to social or occupational environment 
(e.g., agriculture, lorry driver)
Patient age >80 years
Young age of patient (premature infants, babies, infants)
Wounds persisting for >1 year
Wound dimensions of >10 cm2
Chronic wounds of any etiology having a depth of >1.5 cm
Extended inpatient status >3 weeks
Per risk
1 point
2 Severe acquired immune defects (e.g., HIV infection)
Heavily contaminated acute wounds
Bite, stab, and gunshot wounds penetrating 1.5 – 3.5 cm
Per risk
2 points
3 Severe innate immunodeficiency such as Wiskott-Aldrich, Di-George syndrome, 
immunodeficiency after stem cell transplantation, AIDS, immunosuppressive 
therapy [271]
Burn wounds with involvement of >15% BSA
Traumatically contaminated wound after debridement
Wounds that have a direct connection to organs or functional structures 
(e.g., including joints) or which contain foreign material
Bite, stab, and gunshot wounds penetrating >3.5 cm
Per risk
3 points
 Table 4.  Biocompatibility index as a quotient of IC50 for L929 cells 
and the required MIC for a reduction factor of ≥3 log10 [173]
Compound E. coli S. aureus
OCT 1.7 2.1
PHMB 1.5 1.4
PVP-I (aqueous solution, referring on I2) 0.9 1.0
CHD 0.7 0.7
Triclosan 0.2 0.5
Ag-protein (referring Ag+) 0.2 0.1
Ag(I)-sulfadiazine and silver nitrate not measurable
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(HOCl/OCl – ) or sodium hypochlorite (NaOCl) is avail-
able as an additional option. Acetic acid (AA) or combi-
nations with fruit acids such as lactic, malic, citric, fu-
maric, or oxalic acid are gaining increasing interest, in 
particular due to their efficacy against  P. aeruginosa and 
the promotion of wound healing, but also due to their 
availability in countries with limited resources.
 Properties of Selected Antiseptic Active Agents 
 Iodophores and modern compounds such as OCT, PHMB, 
and stabilized hypochlorite meet the requirements for antiseptic 
activity in vitro. Remanent effects are displayed only by OCT, 
PHMB, and CHD. Wound healing is enhanced by PHMB, hypo-
chlorite, and AA depending on the concentration. For PVP-I 
there is an increased risk of sensitization as well as absorptive side 
effects, particularly in thyroid disorders.
 Octenidine 
 In vitro and Animal Experiments 
 OCT shows superior efficacy  [50] in the quantitative 
suspension test without protein load compared with PVP-
I, PHMB, and CHD  [51] . In relation to cytotoxicity, OCT 
is superior to PVP-I  [52, 53] . When tested on metal carri-
ers under load (artificial wound fluid), PVP-I solution was 
effective within in a time frame of 5 min, whereas gels 
based on OCT (0.05%) or PHMB (0.04 or 0.02%) needed 
30 min or 3 h (PHMB 0.02%) to take effect  [39] . PVP-I was 
also most effective in an in vitro wound model with  S. au-
reus , followed by OCT and PHMB  [54] . However, OCT 
showed superior efficacy in a biofilm model with  P. aeru-
ginosa PVP-I  [55] . The  S. aureus biofilm was almost com-
pletely eliminated within 5 min  [56] . Even in experimental 
burns in rats, OCT significantly exceeded both PHMB and 
PVP-I tested against  P. aeruginosa  [57] . CHD interacts 
antagonistically with gentamicin and synergistically with 
OCT  [58] . In vitro, phagocytosis and growth factors, such 
as the platelet-derived growth factor, are stimulated by 
OCT  [59] , which can be beneficial for wound healing.
 Side Effects 
 When OCT/phenoxyethanol (PE) was used in the epi-
cutaneous patch test, a negative response was found for 
OCT, while a positive response to PE and cocamidopro-
pyl betaine was detectable. However, the distinction be-
tween allergic and irritating reactions was inconclusive 
 Table 5.  Properties of wound antiseptics relevant for antimicrobial agents used on wounds
Compound Antimicrobial 
onset time
Deep 
effectb
Development 
of resistance
Wound healing Cartilage 
tolerability
Sensibilization Systemic 
risk
Ag+ ≥24 ha [272] 3 Yes Inhibition [191, 192] ? No Yes [273]
CHD 3 – 10 ha [43] 1 No inhibition [274] No Yes (rare), 
anaphylaxis 
(n >200)
?e
AA 15 – 30 s [49] 2 No At 0.15% supportive 
[229, 275, 276]
?
No
No
OCl– 30 s to 5 minc
[277]
2 Supportive [278] ?
OCT 3 – 10 ha [39] 1d No inhibition [30, 36] No [279] No
PHMB 3 – 10 ha [39] 2 Supportive [94] ≤0.005% [279] Yes (rare), 
anaphylaxis
(n = 3)
PVP-I 30 mina [39] 3 Partial inhibition [172] Yes [279] Yes Yes
 1, superficial effect due to high protein binding; 2, shallow penetration depth; 3, larger than 2.
a Test-carrier (Tc) with organic load [39, 272]. b Due to a lack of experimental data, theoretical extrapolation based on physicochem-
ical properties or demonstrated absorption. c Without load. d In combination with phenoxyethanol 2 or 3. e Possibility of separation of 
4-chloraniline from the chlorhexidine molecule [76].
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 [60] . On the basis of the low absorption determined only 
after removal of the upper skin barrier, no systemic ab-
sorption is to be expected when applied to wounds  [61] .
 Clinical Studies 
 OCT is available as a solution and a gel. The antiseptic 
(OCT/PE) itself as well as the rinse and the gel are well tol-
erated, as shown by studies ( Table 6 ) and case reports  [62–
64] . As an MD (rinse), it is suitable for wound cleansing 
 [62] and supports biofilm removal  [59] . Especially the gel 
is particularly suitable for antisepsis in patients with burn 
injuries. OCT is superior to silver and PVP-I in the latter 
case ( Table 6 ). In the surgical treatment of traumatic am-
putation and splinter injuries which were colonized with 
MDRO, an antibiotic treatment was not necessary after se-
rological and microbiological exclusion of a florid system-
ic infection by antiseptic wound care with OCT/PE in con-
junction with negative pressure wound therapy (NPWT) 
 [65, 66] . With the introduction of a new treatment algo-
rithm for chronic lower leg and foot ulcers in a surgical 
 Table 6.  Summary of clinical study findings for OCT
Type of wound Comparison Result Study design Sample 
size, n
Year
VLU W vs. W with OCT vs. OCT 
wound gel, no difference in 
infection rate at beginning
Wound healing and time to heal 
was significantly better in both 
OCT study arms, lowest costs in 
wound-gel study section
Prospective 
open-label cohort 
study
17/17/15 2016 [280]
VLU W with OCT vs. W with 
silver
OCT showed significantly rapid 
healing and reduction of pain, 
microbial eradication after 28 and 
50 days
RCT 40/40 2015 [281]
Neoplastic ulcer OCT-soaked W; 
comparison baseline vs. 
after 3 weeks of treatment
Significantly faster wound 
healing, significant eradication 
of potentially pathogenic 
Gram-positive and 
Gram-negative bacteria, no 
adverse events
Prospective 
observational study
30 2013 [282]
Split-skin harvest 
sites
OCT-hydrogel vs. hydrogel Significant reduction of wound 
colonization, no difference in 
time to heal
Double-blind RCT 31/30 2012 [36]
VLU OCT/PE vs. Ringer lactate 
solution
No difference in time to heal; for 
OCT fewer adverse events
Double-blind RCT 60/66 2012 [283]
Second-degree 
burn
Irrigation of wound with 
OCT/PE, thereafter OCT gel 
vs. silver sulfadiazine
Significant reduction of pain in 
OCT study arm, tendentially 
improved wound healing; 
possibly no difference observable 
due to initial OCT treatment in 
both study sections
Prospective RCT, 
contralateral site 
served as control
30/30 2011 [284]
Musculoskeletal 
infection
OCT irrigation and drainage 
+ OCT-soaked gauze
After 5 – 24 days eradication of all 
pathogens, no adverse events
Prospective 
observational study
8 2010 [285]
Neoplastic ulcer OCT/PE-soaked gauze; 
comparison of baseline vs. 
after 3 weeks of treatment
Eradication of S. epidermidis and 
P. aeruginosa, reduction of 
necrosis, exudate, erythema, and 
edema; 1× persistence of 
P. aeruginosa, 1× persistence of 
E. coli, and 2× persistence of 
E. faecalis
Prospective 
observational study
16 2008 [286]
 VLU, venous leg ulcer; W, wound dressing.
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outpatient clinic, OCT-based antiseptics were implement-
ed instead of obsolete agents such as CHD, ethacridine, 
H 2 O 2 , silver sulfadiazine, or local antibiotics, with an al-
most 3-fold reduction in the total cost  [67] . OCT was also 
effective in patients with inflammatory acne vulgaris  [68] .
 Caveats 
 During the past few years, several misapplications of 
OCT/PE have been recorded. In these cases, the compound 
was applied in puncture wounds, bite wounds, or abscess 
cavities by syringe with pressure into the wound channel 
and deep tissue, instead of only superficial application. The 
subsequent edematous swellings with tissue damage re-
quired partial surgical revision  [69] . Only superficial ap-
plication by means of swabs or spray is recommended  [70] . 
Any unwanted tissue reactions are improbable in this case, 
because no local pressure necrosis was observed upon 
flushing locally limited skin soft-tissue infections in the 
hand area ( n = 10) with applied drainage  [71] . Since OCT 
is practically not reabsorbed, any insertion into the skin or 
insertion canals is to be avoided. According to the manu-
facturer, the use of OCT/PE for wound treatment without 
medical supervision should not be extended for more than 
2 weeks, as the only data available are from a continuous 
application period of up to approximately 14 days. 
 Contraindications 
 Peritoneal lavage, retroperitoneal and intravenous 
application, allergy, application to hyaline cartilage, and 
CNS structures are contraindications. Interaction with 
CNS structures is recorded for CHD, and is considered 
valid for OCT as well until further data are available  [59] .
 Polihexanide 
 In  1979, Good  [72] combined PHMB, which until 
then had only been used as disinfectant, with polyethyl-
ene glycol 4000 to achieve improved wetting for use on 
wounds  [72, 73] . In the 1980s, PHMB was introduced by 
Willenegger in Switzerland  [74] . PHMB can be seen as a 
virtually detoxified CHD, as the molecular structure of 
PHMB monomers closely resembles the structure of 
CHD molecules, except for the terminal NH-group of 
CHD consisting of 4-chloroaniline, which is a potential 
human carcinogen  [75] . This similarity explains both the 
comparable antiseptic efficacy and the worse tolerability 
of CHD compared to PHMB, due to the release of 4-chlo-
roaniline in vivo  [76] . Depending on the manufacturer, 
wound irrigation solutions release 0.02, 0.04, or 0.1% 
PHMB, wound gel 0.1%, and wound dressings 0.1%. Re-
duction by  ≥ 3 log 10 of typical wound contamination on 
test specimens was achieved by wound gel with a concen-
tration of 0.1% in 30 min, 0.04% in 3 h, and 0.02% in 
10 h.  Enterococcus faecium  was not sufficiently eliminat-
ed in 24 h  [39] . As different concentrations of PHMB 
solutions were not examined on test specimens, it is not 
possible to deduce the optimal concentration for wound 
treatment. A single irrigation of contaminated traumatic 
wounds for 3 min was shown to be effective in a clinical 
trial on the prevention of SSI  [21] , and treatment dura-
tion should not fall below this as long as there are no 
other results. Using wound gel, exposure for at least 3 h 
is needed  [39] .
 Results from in vitro and Animal Tests 
 The efficacy of PHMB does not substantially differ 
from that of OCT. PHMB is equally effective against 
methicillin-sensitive  S. aureus and MRSA  [77] . Higher 
pH levels, which typically develop in wounds (6.5–8.5) 
 [78] , decrease the efficacy of PVP-I but significantly im-
prove that of PHMB. This suggests that PHMB might be 
advantageous for the management of wound infections, 
as both  S. aureus and  P. aeruginosa exhibited increased 
susceptibility to the antiseptic with rising pH levels. The 
inhibitory activity of chlorhexidine and OCT was only 
marginally affected by the pH in vitro, although a statisti-
cally significant improvement was observed against  S. au-
reus at pH 9 for OCT  [79] .
 In combination with undecylenamidopropyl betaine 
(Betaine), the antimicrobial effect is enhanced because 
of altered physical properties  [80, 81] , while in vitro cy-
totoxicity is reduced  [80] and cleaning performance is 
improved  [82] ; the latter one could not be confirmed in 
a newer study because of the interference of the surfac-
tant with the protein measurement [322]. Intracellular 
elimination is remarkable, as shown for  E. coli  [83] , 
MRSA  [84] , and  Acantha moeba species  [85] . Thus, 
PHMB (0.02%) is the preferred agent for the treatment 
of  Acanthamoeba keratitis  [85] . Efficacy against  P. ae-
ruginosa can still be observed in the presence of 4% al-
bumin  [86] , 4.5% blood + 4.5% albumin  [87] , and 
wound exudates, while the expression of elastase is in-
hibited at the same time  [88] . In a wound model on pigs, 
MRSA was significantly reduced after 72 h by PHMB in 
a wound treatment matrix based on collagen, while sil-
ver dressings were ineffective  [89] . PHMB was effective 
against biofilm in vitro  [90] and in animal models  [91] . 
Loaded onto nanocellulose, PHMB was antimicrobially 
more effective than PVP-I  [92] . No antagonism could 
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be shown against oxacillin, penicillin G, ampicillin, ce-
fazolin, cefuroxime, imipenem, gentamicin, erythro-
mycin, doxycycline, levofloxacin, linezolid, or vanco-
mycin  [93] . Both in cell culture and animal wound 
models (rat, pig), wound healing was improved  [31, 94–
96] . Results of in vitro and animal tests (rat) are prom-
ising for the combination of PHMB and sericine, an 
ameliorator of wound healing, in a dressing  [97] . Capil-
lary density was significantly increased in the cremaster 
muscle (rat) by exposure to PHMB and OCT, while the 
diameter of arterioles was significantly increased only 
by PHMB  [98] . The irritation potency of 0.02% PHMB 
is lower than that of antibiotic eye drops  [99] .
 In 2011, the Committee for Risk Assessment of the 
European Chemicals Agency (ECHA) raised the suspi-
cion that PHMB was a category-2 carcinogen (Carc. 2). 
Consequently, all products containing PHMB in a con-
centration of at least 1% had to be labeled accordingly 
from January 1, 2015. Compositions containing 0.1% re-
quired an annotation on the safety data sheet. This clas-
sification by the ECHA as category 2 “suspected of caus-
ing cancer” lacks scientific proof. The 2 studies used for 
the evaluation were feeding studies using extremely high 
PHMB concentrations far in excess of the no-observed-
(adverse-)effect level. Only in the highest tested concen-
tration of 4,000 ppm did the frequency of cases with hem-
angiosarcoma significantly increase, but at  ≤ 1,200 ppm 
this was not the case. Neither genotoxicity nor epigenetic 
changes  [100] could be shown; therefore, it is very likely 
that hemangiosarcoma was triggered by enforced prolif-
eration of the endothelium, as was proven for PHMB in 
wound healing. For risk assessment, it is critical that there 
be no systemic absorption up to the detection threshold 
of 10 μg for PHMB, so a health hazard can be excluded 
for antiseptic use according to regulations [detailed state-
ment with references in 101, 102].
 It is important to note that, in this context, the ECHA 
specifically excluded PHMB from the labeling require-
ments when used invasively or on the skin surface for 
wound irrigation or with dressings. The reason for this 
exemption is the regulatory classification of hazardous 
substances and their preparation to ensure occupation-
al and environmental safety. Particularly exposure to 
larger amounts, which is possible during the produc-
tion of these substances, has to be considered. Person-
nel should be appropriately protected against critical 
exposure.
 Undesirable Effects 
 Two cases of a possible anaphylactic reaction triggered 
by PHMB could not be verified in the skin-prick test 
 [103] . One patient with a grade III anaphylactic reaction 
had IgE against both PHMB and CHD. Due to the similar 
structures, it is discussed that sensitization was caused by 
a prior treatment with CHD, so a known allergy against 
CHD might be linked to a risk for PHMB anaphylaxis 
 [104] . In the second case, only IgE against PHMB was 
proven  [105] . A further suspected case of anaphylaxis was 
reported after wound application  [106] . Contact allergies 
are rare, with a frequency of  ≤ 0.08% in regard to the fre-
quent use of PHMB, especially as a preservative  [107] . 
This suggests that antiseptic substances should be limited 
to medical applications.
 Clinical Trials 
 PHMB is available as a solution, hydrogel, and in 
wound dressings  [108] . It is well tolerated  [109] , anti-
septically effective against MRSA and VRE (vancomy-
cin-resistant  Enterococcus )  [110–112] , can be used for 
wound irrigation, is suitable as an antiseptic for criti-
cally colonized and infected chronic wounds, including 
burns  [37, 94, 113–124] , and, in combination with 
NPWT, can be used for instillation (NPWTi). It is supe-
rior to Ag + and PVP-I regarding wound healing  [123] 
( Table 7 ). Upon application of wound dressings impreg-
nated with 0.2% PHMB, epidermally applied  Staphylo-
coccus epidermidis were completely eliminated in 24 h 
 [125] . The same was shown for  P. aeruginosa in an ani-
mal model  [126] . Application for pre- and postoperative 
wound treatment significantly reduced the rate of SSI 
( Table 7 ). Cytotoxically, wound dressings do not differ 
from PHMB-free dressings  [127] . After a 4-week unsuc-
cessful treatment of a diabetic foot ulcer with PHMB/
betaine gel, the healing process commenced after a 
4-week treatment with OCT gel  [128] . In cases with hu-
man papillomavirus infection, the viral elimination was 
significantly improved by local treatment with PHMB, 
examined after 3 and 6 months, which could open a new 
area of application  [129] .
 Caveats 
 Due to the relatively strong binding onto tissue struc-
tures, the same restrictions as those for OCT should ap-
ply, although no clinical reports are available yet. This is 
supported by the appearance of grayish, inert tissue after 
retroperitoneal, mediastinal, and partially inguinal appli-
cation for more than 5–10 days. This tissue had to be re-
moved in order to permit the formation of granulation 
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 Table 7.  Summary of clinical study findings for PHMB
Type of wound Comparison Result Study design Sample 
size, n
Year
Traumatic soft tissue 
injuries
0.04% PHMB, 1% 
PVP-I, 4% WPO, 
Ringer solution 
SSI rate: 1.9/4.8/11.7/5.9; PHMB was 
more effective in preventing infection 
in deep incisional wounds (A1 and 
A2 SSI), in contusion wounds only in 
A2 SSI
Longitudinal 
cohort study
3,264/
2,552/
643/645
2017 [21]
Pressure and VLU PHMB/betaine 
solution vs. NaCl 
solution
Significant improvement of 
inflammation and wound healing, 
no difference in pain scores
Single-blinded 
RCT
143/146 2016 [287]
Wounds in elderly 
patients
PHMB/betaine 
solution
Significant decolonization with 32% 
success (p < 0.05)
Prospective 
controlled 
nonrandomized 
open-label study
200/99 2016 [112]
Nonhealing wounds 
after cardiothoracic 
surgery 
PHMB 0.5% vs. moist 
gauze soaked with 
Ringer solution
Superficial infection 38 vs. 47%, (ns), 
deep infection 44 vs. 40% (ns), 
wound healing after 15 ± 5 vs. 16 ± 3 
days (ns); wound healing in 67 vs. 
44% (ns); PHMB: patients without 
complete wound healing showed 
better epithelialization, after 12 h 
CRP was significantly lower than 
controls
Prospective open 
randomized 
cohort study
15/16 2015 [288]
Chronic wounds PHMB gel vs. betaine 
gel
Significant reduction in wound size, 
pain, fibrin slough, and necrosis; 
reduction of exudate
Multicenter 
observational 
study
120 2014 [289]
Grade II burns PHMB gel vs. betaine 
gel
Less pain medication, good progress 
in wound healing with formation of 
granulation tissue and 
epithelialization; reduction of 
erythema after 2 days; no infection 
during mean treatment of 11.2 days
Observational 
study
20 2014 [290]
Postsurgical 
subcutaneous 
abdominal infections
NPWTi with 0.04% 
PHMB-soaked gauze 
vs. NPWT
Reduced duration of treatment Prospective 
case-control 
study
16 2014 [291]
Wounds after 
cardiothoracic 
surgery
W vs. W+PHBM PHMB: significant decrease of SSI Cohort study 692/707 2013 [292]
Critically colonized 
and infected chronic 
wounds
PHMB vs. Ag-W PHMB: significantly faster pain 
reduction and elimination of 
microorganisms
RCT 21/18 2012 [293]
Entry point of 
external fixator 
W vs. W+PHBM PHMB: significant decrease of SSI RCT 18/22 2012 [294]
Lower-limb and foot 
ulcers
W vs. W+PHBM PHMB: significantly faster pain 
reduction and elimination of 
microorganisms, tendentially 
faster wound healing
Double-blinded 
RCT
22/23 2011 [295]
Burns W vs. W+PHBM PHMB: significant pain reduction 
and fewer dressing changes
RCT 30/30 2011 [296]
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tissue, even after infection control independent of PHMB 
use as a single substance or in combination with betaine 
( Fig. 1 a, b).
 Contraindications 
 The 2 most important contraindications are possible 
allergy and application during the first 4 months of preg-
nancy. In later stages its use should follow strict obser-
vance of a benefit-risk assessment.
 Sodium Hypochlorite/Hypochlorous Acid 
 The successful stabilization of the combination 
NaOCl/HOCl provided an ecologically relevant new de-
velopment, because aqueous sodium chloride solution is 
electrochemically converted for its production. The acti-
vated solution is also called electrolyzed water  [130] . The 
currently used concentration amounts are 0.004% each 
for NaOCl and HOCl, and <0.06% for NaOCl as a mono-
substance. In contrast to surface-active substances, the 
ion OCl – is formed during phagocytosis through enzyme 
mediation by myeloperoxidase, eosinophilic peroxidase, 
and superoxide dismutase, and presents a physiological 
bactericidal mechanism  [131] .
 Results from in vitro and Animal Tests 
 In tests without wound-related contamination, e.g., 
proteins or blood, and more specifically only in aqueous 
solution, NaOCl/HOCl and NaOCl are highly effective 
against vegetative bacteria, bacterial spores, aspergilli, oo-
cysts of cryptosporidia, and coated viruses (HIV, HBV). 
Type of wound Comparison Result Study design Sample 
size, n
Year
Split-skin harvest 
sites
CHD W vs. PHMB W PHMB: significantly faster 
reepithelialization and lower pain 
score
RCT 21/21 2011 [297]
Infected orthopedic 
implants
NPWTi with PHMB 
0.04%
86% of patients with acute and 80% 
of patients with late-onset infections 
kept their implant during a follow-up 
time of 4 – 6 months
Prospective 
multicenter 
observational 
study
32 2011 [298]
VLU NaCl vs. PHMB 
solution
PHMB: significantly faster bacterial 
elimination
Prospective 
cohort study
20/20 2010 [299]
Postsurgical wounds W vs. W+PHMB 
0.2%
(first and possibly 
second dressing after 
surgical procedure)
PHMB: significant reduction in SSI, 
particularly of MRSA infection
Historic 
comparison
9,372/
10,202
2008 [300]
Chronic wounds NaCl vs. 0.1% PHMB 
gel 
PHMB: after 2 weeks significantly 
faster bacterial elimination, faster 
wound healing, less pain, less 
exudate, improved granulation
Randomized 
nonblinded 
cohort study
64/78 2008 [301]
Burns PVP-I, 1% silver 
nitrate, 0.04% PHMB
PHMB: improved epithelialization 
and elimination of malodor; deep 
necrosis and slough observed in 
PVP-I and silver nitrate study section
Parallel 
intervention on 
contralateral 
symmetric wounds 
4 2007 [113]
Acute contaminated 
wounds 
PHMB-wetted gauze 
(0.04%) vs. Ringer 
solution
Significant faster bacterial 
elimination, reduction of 
inflammation
Double-blinded 
RCT
28/22 2006 [302]
Infected wounds W vs. W+PHBM PHMB: improved control of wound 
colonization
RCT 21/21 2004 [303]
 NPWTi, negative pressure wound therapy with instillation of antiseptics; W, wound dressing.
Table 7 (continued)
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The combination of PHMB/betaine was slightly less ef-
fective than NaOCl/HOCl against biofilm  [132] . The 
speed of effect was superior to PVP-I, OCT, and PHMB 
 [130, 133–137] . It can be assumed that the efficacy is re-
duced by protein or blood contamination, which can be 
reversed by repetitive extensive wound irrigation. The 
survival rate of rats with experimental peritonitis was sig-
nificantly increased compared to a treatment with NaCl 
without undesirable effects  [138] . By stabilization of the 
cell membrane, the release of cytokines from mast cells is 
inhibited without intracellular impairment, possibly con-
tributing to an anti-inflammatory effect  [29] . NaOCl/
HOCl was not or barely irritating on chick chorioallan-
toic membranes [323]. Furthermore, no evidence for cy-
totoxicity could be found in a 3D model of the skin [132]. 
There is no evidence for toxic risks  [139] . The feeding of 
laboratory animals with 5 ppm is a safe alternative instead 
of sterile water  [140] . There is no evidence that NaOCl 
poses a carcinogenic hazard  [141, 142] . 
a b
 Fig. 1. Retroperitoneal instillation with PHMB on an aortal endoprosthesis infection.  a Situs after 14 days and 
multiple excisions of the yellowish-brownish slough within 10 days.  b Situs after a 16-day instillation with phys-
iological NaCl solution. Source: D. Mayer. 
a b
 Fig. 2. A 90-year-old patient after excision of an ulcus hypertonicum Martorell and coverage with a split-skin 
mesh.  a In due course, the formation of slightly bleeding, instable hypergranulations, which are possibly a sign 
of incipient infection.  b After 2.5 weeks of daily dressing change and coverage with a Betadine gauze, the hyper-
granulations regressed and stable granulation tissue developed with a marked swelling of the wound vicinity. 
Source: D. Mayer. 
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 Undesirable Effects 
 Rinsing of the mediastinum in heart surgery with 
NaOCl/HOCl prior to wound closure was significantly 
associated with perioperative alterations of the ECG, in-
cluding ST elevation, but without hemodynamic distur-
bances  [143] .
 Clinical Trials 
 Case studies on NaOCl/HOCl report decolonization 
of MRSA infections on skin and the base of the skull  [144, 
145] , decolonization of MRSA,  P. aeruginosa , and  E. coli 
in chronic diabetic ulcers  [146] , and successful adjuvant 
application in the treatment of necrotizing soft tissue in-
fection  [147] , osteitis  [145] , and osteomyelitis  [148] . In 
cases of peritonitis, partially with peritoneal abscess ( n = 
7), no bacterial growth was detectable 3–7 days after ir-
rigating twice daily for 9–12 days  [149] . Postoperative 
complications including SSI were significantly reduced in 
patients with peritonitis without symptoms of intoler-
ance  [150] . The irrigation of infected chronic wounds was 
well tolerated  [151] , also in combination with NPWT 
 [152] . The combination NaOCl/HOCl with a hydropho-
bically coated wound dressing, to which microorganisms 
adhere and bind irreversibly, appears promising and to 
lack the subsequent physiological immune response im-
pairment that is triggered by OCl – ( Table 8 ).
 Iodophore 
 The introduction of iodophores, complexes of iodine 
and macromolecules, in 1956 sparked a renaissance of an-
tisepsis. However, demands for stricter indications were 
already made in 1984, with a call for each specialty to 
more rigorously watch for undesired effects to prefer an 
antiseptic agent with similar antimicrobial spectrum but 
fewer undesirable effects  [153] . Especially the risk of thy-
roid gland dysfunction, but also the relatively high po-
tency for allergic sensitization, has led to a restricted ap-
plication of PVP-I during recent years.
 The macromolecular carrier system of PVP and the 
release of iodine after degradation by reacting agents re-
sult in lower iodine absorption, cytotoxicity, and sensiti-
zation, and thus in better tolerability than aqueous or al-
coholic iodine solutions. In aqueous solutions, only a 
thousandth of the total iodine is free and microbicidally 
active. The development of liposomal PVP-I composi-
tions (PVP-I-L) on the basis of hydrogel improved the 
wound tolerability  [30, 154] . 
 In contrast to PVP-I, cadexomer-iodine (C-I) uses a 
hydrophilic, modified starch polymer to embed iodide 
ions. The advantages of C-I are similar to those of PVP-I; 
however, PVP-I and C-I show different properties re-
garding the reactivity of iodine and water absorption 
 [155] . C-I did not become as widespread in German-
speaking regions as PVP-I did.
 In vitro and Animal Experiments 
 The microbicidal effect is observed for all vegetative 
pathogens, including mycobacteria, yeasts, and dermato-
phytes, enveloped and nonenveloped viruses (including 
rabies especially in combination with alcohols), as well as 
protozoa, and, with a longer exposure time (2–24 h), also 
bacterial spores  [156] . Depending on the test model, the 
efficacy of PVP-I in vitro can be higher than, comparable 
to, or less than OCT and PHMB; 10% sheep blood does 
not affect the efficacy. In 10% serum albumin as well as 
4.5% sheep blood + 4.5% serum albumin + 1% mucin, the 
exposure time doubles, similar to OCT  [38, 39] . In con-
trast to OCT and PHMB, PVP-I has no remanent effect. 
Extended antiseptic effects, shown in vitro, are not due to 
a true remanent effect in PVP-I, in contrast to OCT or 
CHD, but are an artifact of the modified release kinetics 
of the iodine from the PVP molecule, which follows the 
second order of kinetics.
 In vitro, PVP-I inhibits the formation and release of in-
flammatory mediators due to the reducted expression of 
bacterial exotoxins, the inhibition of excessive mediator 
molecule release, and the activity of human immune effec-
tor cells, as well as the inactivation of tissue-destroying en-
zymes  [157, 158] . Through chemical reactions with the 
physiological H 2 O 2 peroxidase systems, oxidation products 
with a higher efficacy than that of molecular iodine can be 
formed in wounds  [156] . C-I ex vivo and in animal models 
has a strong effect against biofilm-forming  S. aureus and  P. 
aeruginosa  [159] . The contrasting effects against biofilms 
are attributed to the different availability of active iodine in 
the various forms administrated  [160] . In animal experi-
ments, the healing of skin wounds was significantly delayed 
by 2% PVP-I  [161] . For PVP-I-L, proliferation and im-
provement of microcirculation have been demonstrated in 
in vitro and animal experiments  [30, 162, 163] . In animal 
models, the application of C-I promotes epithelial cell re-
generation and thus wound healing  [164, 165] . In PAOD 
(peripheral arterial occlusive disease)-associated ulcers, C-I 
was tolerated without irritation  [166] . In accordance with 
this, in histological tests, no tissue damage was observed in 
the treatment of chronic exudative wounds  [167] . There is 
no evidence of neurotoxicity, mutagenicity, carcinogenici-
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ty, or teratogenicity  [156, 168] . In the cell culture (fibro-
blasts), 0.45% C-I was found to be noncytotoxic  [167] .
 Side Effects 
 Iodophores display a high sensitization potential  [169] . 
In adults with no known thyroid disease, and in contrast 
to premature infants and newborns as well as small chil-
dren, irreversible damage to the thyroid gland is not to be 
expected after a single antiseptic application of PVP-I. 
However, even in patients who do not have a thyroid con-
dition, PVP-I should not be used for more than 7 days due 
to a risk of thyroid dysfunction  [156] . Rare extrathyroidal 
side effects have been described, such as iodine acne, run-
ny nose, conjunctivitis, gastroenteritis, bronchitis, parotid 
swelling, and renal impairment  [170] . In the case of C-I 
application, temporary pain may also occur  [171] .
 Clinical Studies 
 Clinically, wound healing was generally not impaired 
by PVP-I. However, in some cases the control group had 
a better outcome  [172] , probably promoted by C-I  [165] , 
although PVP-I showed worse results than OCT and 
PHMB in terms of biocompatibility  [173] . On the one 
hand, PVP-I has been shown to be less comfortable than 
medical honey and less effective in reducing the wound 
size than silver dressings  [174] , but on the other hand, it 
was superior to silver and C-I dressings regarding the 
amount of pain during medical dressing changes  [175] .
 Table 8.  Summary of clinical study findings for the combination NaOCl/HOCl
Type of wound Comparison Result Study design Sample size, 
n
Year
Explorative laparotomy/
peritonitis
NaOCl/HOCl vs. 
NaCl
OCl: significant reduction of fever and 
prevention of SSI
RCT 50/50 2013 [150]
Diabetic foot ulcers, 
VLU, burns
NaOCl/HOCl vs. 
PVP-I
OCl: faster granulation and 
epithelialization, faster reduction of wound 
size, reduction of surrounding edema and 
erythema, better cosmetic results in burn 
wounds; PVP-I: minute skin irritation and 
pain in burns
RCT 100/100 2011 [304]
Chronic wounds, SSI NaOCl/HOCl vs. 
PVP-I
OCl: significant wound size reduction, 
fewer persisting infections due to 
P. aeruginosa, S. aureus, and Klebsiella spp. 
RCT 50/50 2011 [305]
Diabetic foot ulcers NaOCl/HOCl vs. 
PVP-I
OCl: significantly better wound healing, 
control of infection, significantly more 
interventions in the PVP-I study section
RCT 20/20 2010 [306]
Chronic wounds NaOCl/HOCl vs. 
PVP-I
OCl: significant wound size reduction, 
better control of microbial colonization; was 
well tolerated
RCT 15/15 2009 [307]
Diabetic wounds NaOCl/HOCl vs. 
NaCl (soaked 
gauze)
OCl: significantly reduced hospitalization 
and wound size, improvement in wound 
score
Blinded 
RCT
50/50 2007 [278]
Diabetic foot ulcers NaOCl/HOCl vs. 
PVP-I 
OCl: significant reduction of malodor, 
significant reduction of soft tissue infection, 
improved granulation, lower occurrence of 
erythema
Blinded 
RCT
21/16 2007 [308]
Diabetic foot ulcers NaOCl/HOCl vs. 
PVP-I
OCl: reduced treatment time RCT 110/108 2005 [309]
Burns NaOCl/HOCl vs. 
Ag
OCl: 11% reduction in use of antibiotics, 
50% reduction in hospitalization
Retrospective 
cohort study 
64/64 2005 [310]
SSIs NaOCl/HOCl vs.
PVP-I
OCl: significantly reduced hospitalization 
and reduction of pain
Retrospective 
cohort study
46/42 2001 [311]
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 In a prospective randomized controlled trial (RCT), 
PVP-I-L was significantly more effective and tolerable 
than a CHD-impregnated layer on a mesh graft  [30] . Over-
all, iodophores offer no significant advantages over PHMB, 
active ingredients and wound dressings containing silver, 
medical honey, and nonantiseptic treatments. Exploitation 
of the antiseptic and cytotoxic properties of iodine in the 
treatment of pathological granulation tissue or hypergran-
ulation tissue is of particular interest in wound healing. 
This is due to the mode of action, i.e., the pathophysiolog-
ical approach of preventing tissue destruction by combat-
ing the “low-grade” infection ( Fig. 2 a, b), unlike in conven-
tional methods, such as silver nitrate etching or surgical 
resection. Within 2–3 weeks of treatment with iodine 
gauze, fragile, bleeding hypergranulation tissue transforms 
into stable, healthy, vital granulation tissue.
 Caveats 
 Considering the broad availability of new antiseptics, 
the application of iodophores must be evaluated carefully 
 [176] . If PVP-I is continuously used, thyroid function 
must be checked in patients with euthyroid goiter, or in 
patients with any known thyroid disease, during preg-
nancy and lactation, and before extensive use in prema-
ture and newborn infants, as well as in infants up to 6 
months old. Because of its cytotoxicity, repeated use is not 
recommended in chronic wounds, especially on trans-
planted mesh grafts (this does not apply to PVP-I-L). 
 Contraindications 
 PVP-I allergy, hyperthyroid goiter, dermatitis herpeti-
formis Duhring, use before and after radioiodine treat-
ments, as well as peritoneal lavage  [156] contradict the 
use of C-I. Hashimoto’s thyroiditis, pregnancy, lactation, 
and an age below 12 years are additional contraindica-
tions for C-I  [171] .
 Taurolidine 
 Taurolidine was introduced in 1981, and although ini-
tial results seemed promising, scientific studies still show 
unsatisfactory results.
 In vitro and Animal Experiments 
 Due to the slow elimination of the formaldehyde mol-
ecule, the antiseptic efficacy of taurolidine only begins af-
ter 6–24 h in vitro  [177] . Therefore, antiseptic efficacy can 
only be expected in long-term applications. Another 
mode of action is based on the antiendotoxin effect of the 
cross-linking of muramyl peptides in the bacterial cell 
wall by transferring methylol groups from the taurolidine 
molecule. This is intended to reduce the release of inflam-
matory mediators. In peritonitis, the inflammatory-in-
duced serum levels of TNF-α and interleukin-1 decreased, 
and the survival rate increased after the application of 
taurolidine  [178, 179] . Furthermore, the activity of fibro-
blasts, the hydroxyproline tissue levels, and the mechani-
cal stability in anastomoses increased  [180] . In a mono-
layer cell culture of human amniotic cells, no cytotoxicity 
was detected even with complete replacement of the cell 
culture medium by taurolidine 2%  [181] . On peritoneal 
explants, taurolidine Ringer 0.5% was completely toler-
ated (with a slight increase of growth promotion). Re-
garding the tolerability of peritoneal explants, taurolidine 
2% was comparable to 0.04% PHMB  [182] . Despite the 
good in vitro tolerability of taurolidine, epithelialization 
was significantly delayed in secondary wound healing in 
the animal model (rat)  [183] .
 Clinical Studies 
 Despite the the expectactions due to the mechanism of 
action and the proven partial reduction of the bacterial 
count in the peritoneum, the outcome did not verifiably 
improve after a prophylactic peritoneal lavage  [184] , nor 
did it improve the outcome when treating sepsis and vari-
ous forms of peritonitis  [185–188] , compared to rinsing 
with physiological NaCl solution. After a first unsuccessful 
treatment of septic ulcers with 0.04% PHMB or 8-quinoli-
nol, bacteria were eliminated after changing to taurolidine 
2% (soaked dressings) after 2, 6, and 7 days. Although a 
patient showed a slower elimination of bacteria, his status 
continuously improved and the wound showed good epi-
thelization after 28 days, such that the patient could be 
transferred to outpatient treatment  [189] . Because of as-
sociated pain, taurolidine had to be combined with a local 
anesthetic. Due to limited data, currently taurolidine can-
not be recommended for wound antisepsis.
 Silver Ions 
 Silver-releasing compounds have been used since an-
cient times for wound treatment. However, silver in its 
elemental form has no antimicrobial effect. Antimicro-
bial activity develops only after the silver atoms lose an 
electron and become positively charged silver ions.
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 In vitro and Animal Experiments 
 Silver ions bind to peptide glycans of the bacterial cell 
membranes and thus lead to their destruction. Silver ions, 
which are transported into the cell, interfere with numer-
ous cell functions by binding to proteins and interfering 
with energy generation, enzyme function, and cell repli-
cation. Thanks to these diverse points of attack, the devel-
opment of resistances against silver ions has to date only 
been rarely described  [190]. 
 Clinical Studies 
 A great practical problem in the evaluation of wound 
therapeutics with silver is based on the extreme heteroge-
neity of the products. Thus, it is not surprising that 2 
Cochrane meta-analyses  [191, 192] have come to the fol-
lowing conclusions: silver can inhibit wound secretion 
and odor, and some studies showed a promotion of 
wound healing, but other studies showed a delay in wound 
healing. Currently, there are not enough studies with 
high-level evidence for a general recommendation of sil-
ver-containing wound dressings to improve wound heal-
ing or to treat or prevent wound infections. However, this 
also applies to most other antiseptic therapeutics used for 
wound treatment. A recent meta-analysis of clinical trials 
over the last 15 years shows that out of 39 clinical trials on 
the subject of silver in wound treatment, 31 were RCTs. 
In 28 of the 39 controlled studies, positive aspects were 
described for wounds, such as accelerated wound healing 
and bacterial reduction as well as positive aspects in qual-
ity of life or pain reduction. On the basis of an expert rec-
ommendation, the use of silver in the treatment of criti-
cally colonized or infected wounds, as well as in the case 
of a detected MDRO, was recommended for a maximum 
of 14 days. After this period, a critical reevaluation of the 
usefulness of silver-ion therapy should be performed. 
However, an extensive, long-term and prophylactic use 
was not recommended  [190] .
 Inadvisable or Obsolete Agents 
 CHD has now generally been replaced by OCT, 
PHMB, and, in the case of acute bite wounds, PVP-I. 
The reasons for this are the risk of anaphylactic reac-
tions  [193] , the progressive development of resistant mi-
crobes, and the increased cytotoxicity compared to OCT 
und PHMB. Topical silversulfadiazine has lost its sig-
nificance based on recommendations to avoid the topi-
cal use of chemotherapeutics, its cytotoxicity, its risk of 
absorptive side effects, and the unwanted formation of 
hardly soluble complexes between the cream and wound 
proteins making wound analysis (burn depth detection) 
virtually impossible in burn patients. Therefore, the in-
dication for necessary surgical treatment in patients 
with deep second-degree burns may be overlooked or 
delayed due to the adherent scab  [194] . Chinolinole 
 [195] and nitrofural  [196] do not meet the formal re-
quirements of an effective antiseptic agent, nor are there 
convincing clinical data proving their efficacy. More-
over, both agents bear toxic risks, and the risk-benefit 
analysis speaks against their use. Dyes, organic mercury 
compounds, pure H 2 O 2 , as well as topical antibiotics, are 
considered obsolete  [194] .
 Recommended Antiseptic Agents 
 Table 10 shows a comparison of indications for most 
antiseptics (no comparative studies exist between 
NaOCl/HOCl, OCT and PHMB) according to the litera-
ture.
 OCT: The combination 0.1% OCT/PE solution is suit-
able for acute, contaminated, and traumatic wounds, in-
cluding MRSA-colonized wounds, due to its deep action. 
For chronic wounds, preparations with 0.05% OCT are 
preferable. The latter are available as gels or rinses com-
bined with surface-active ethylhexylglycerin.
 PHMB: The following recommendations can be made 
according to a literature review: level A (= strong support 
that merits application): therapeutic option for acute trau-
matic wounds, chronic ulcers and second-degree burns 
due to its analgesic effect; level B (= moderate support that 
warrants consideration of application): (cost-)effective 
treatment of wound infections, promotion of wound heal-
ing, and treatment of moderately exuding recalcitrant 
wounds  [197] . Therefore, PHMB may be considered the 
first-choice agent for infected chronic wounds and burn 
wounds (gel, dressing). Furthermore, PHMB efficiently 
decolonizes MRSA in chronic wounds. In surgery, PHMB 
reduced the rate of SSI after primary debridement, placing 
external fixator entry ports, and poststernotomy sutures 
after cardiac surgery. However, due to its retrospective co-
hort study design and small sample size ( Table 7 ), more 
evidence is needed for the latter indications. Given its 
spectrum of activity, PHMB is considered active against 
Gram-negative MDROs. However, the results of broad-
spectrum tests leave some doubt as to whether PHMB is 
an effective agent for the treatment of VRE  [39] .
 Hypochlorite: NaOCl or NaOCl/HOCl are first-choice 
agents for single or repetitive intensive, antiseptic cleans-
 Kramer/Dissemond/Kim/Willy/Mayer/
Papke/Tuchmann/Assadian
 
 Skin Pharmacol Physiol 2018;31:28–58 
DOI: 10.1159/000481545
44
ing of contaminated traumatic wounds and for the re-
petitive antiseptic cleansing of chronic wounds for the 
duration of the cleaning phase. Colonization with MRSA 
is effectively eradicated. OCl – may even be used for anti-
sepsis when structures of the CNS are exposed or, in the 
case of peritonitis, as an antiseptic agent for peritoneal 
lavage.
 PVP-I: a recent systematic review  [172] concludes that 
PVP-I should no longer be used in the treatment of 
chronic wounds. This, however, does not apply to liposo-
mal PVP-I (PVP-I-L), as epithelialization is promoted 
 [198] . Detailed studies investigating improved PVP-I for-
mulations are lacking; thus, the effectiveness of PVP-I-L 
on healing of chronic wounds cannot definitely be as-
sessed at this stage. There is a lack of evidence for the use 
of PVP-I as a cleaning solution for the prevention of SSI 
in acute traumatic soft tissue injuries  [21] . However, in 
combination with alcohol, e.g., ethanol, PVP-I is still the 
first-choice agent for infection prevention in acute stab, 
cut, bite, or gunshot wounds due to its ability to penetrate 
deeply into the wounds  [199] . Its excellent tissue penetra-
tion makes PVP-I (only on an aqueous basis!) a possible 
candidate for use in the heavily destroyed tissue of trau-
matic wounds, such as those resulting from car-crashes 
or explosions.
 Basic Rules of Antiseptic Treatment in Wound 
Management, Based on Wound Type 
 Before the application of an antiseptic agent, the following 
rules must be considered  [200] :
 – Determine the correct diagnosis (i.e., etiology) of any chron-
ic, nonhealing wound! The best antiseptic is ineffective if the 
initial cause for infection is not treated.  
 – Cleansing and debridement of (chronic) wounds are crucial! 
Otherwise, antiseptics are ineffective.  
 – Manage any wound according to its healing phase, especially 
regarding wound dressings  [201] . Every dressing change 
should be done meticulously following basic antiseptic rules 
 [202] . 
 As a matter of principle, the therapeutic regimen 
should be reviewed after 2 weeks of unsuccessful appli-
cation of an antiseptic, including further diagnostics 
and, for example, analyzing local blood flow in order to 
avoid continuing an unsuccessful regimen ad infini-
tum. Although rinses usually do not have a predeter-
mined limit for the duration of their application due to 
their status as an MD, this practice should also be im-
plemented when treatment with these solutions proves 
unsuccessful.
 Bite and Stab Injuries  [199, 203] 
 Acute open wounds should be thoroughly debrided 
and rinsed with PVP-I/alcohol. In case of contraindica-
tions, OCT/PE is a promising option. In the first 4 h, no 
antibiotic prophylaxis is needed and open wound treat-
ment is continued. 
 In the case of virtually “closed” acute injuries (e.g., cat 
bites), deep surgical debridement must be carried out and 
the wound should be covered by a PVP-I/alcohol- or 
OCT/PE-soaked dressing. Alternatively, if a distal pha-
lanx is involved, for example, the finger could be im-
mersed in a PVP-I/alcohol or OCT/PE bath. PHMB does 
not exhibit a deep effect without adjuncts enhancing deep 
penetration. The penetration depth for hypochlorites is 
unknown.
 For injuries or wounds older than 4 h, besides follow-
ing the above rules, antibiotics should be administered 
orally or intravenously according to current guidelines 
(e.g., empirical evidence supports starting with ampicillin 
or amoxicillin; in most cases, a single injection will suf-
fice).
 For  injuries or wounds older than 24 h, the same rules 
apply. However, if the wound seems clinically inflamed 
or infected, excision should be considered and antibiotics 
are usually administered for a longer period. Surface-ac-
tive antiseptics should not be applied under pressure and 
continuous drainage should be guaranteed.
 Burns 
 For possibly lethal cases, the administration of broad-
spectrum antibiotics is crucial. After necrosectomy and 
escharotomy, the wounds and, later, freshly applied skin 
grafts are continuously moistened with antiseptics. Adju-
vant systemic treatment consists of specific, adequate nu-
tritional support and the substitution of factors that pro-
mote wound healing  [204] . However, smaller burns can 
be managed and healed conservatively using antiseptic 
dressings  [205] . Antiseptics of choice are gels on the basis 
of PHMB. The effectiveness of devices and dressings con-
taining silver ions remains unclear  [191, 192, 194, 206, 
207, 272] . 
 Antiseptic Irrigation/Rinsing 
 It has been shown that a single irrigation/rinse with an 
antiseptic agent reduces the SSI rate after surgical man-
agement of acute, contaminated wounds  [21] . The same 
holds true for intraoperative irrigation/rinsing before 
surgical wound closure  [208] .
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 Decolonization of MRSA-Colonized Wounds 
 The main indication for decolonization is to prevent 
the spread of nosocomial infections. Decolonization of 
MRSA in the nasal vestibule is usually successful after 7 
days  [209] . Burn wounds are decolonized after 5 days 
 [210] , whereas chronic wounds need to be treated with 
mupirocin for 14 days  [211, 212] .
 Treatment of Locally Infected or Critically Colonized 
Wounds 
 For these types of wounds, routine treatment with an 
antiseptic agent is required (examples are given in  Tables 
6–9 ).
 Future Perspectives 
 NPWT with Instillation of Antiseptic Agents 
 NPWT exerts no direct antimicrobial effect. Therefore, instil-
lation of an antiseptic agent in combination with NPWT, called 
NPWTi, is being increasingly promoted as a promising combina-
tion in wounds with a heavy bioburden  [213–218] .
 NPWT may be considered a special form of semiocclu-
sive “moist” wound dressing with virtually unlimited 
drainage capacity. Through direct contact and interaction 
of the foam with the wound, the granulation process is pro-
moted  [216] and tissue perfusion improved  [219] . In an 
animal model, where excision wounds on the back of pigs 
were infected with  P. aeruginosa , instillation of physiolog-
ical NaCl combined with NPWT (NPWTi) was clearly 
more effective in reducing the bioburden than NPWT 
alone; instillation with PHMB significantly enhanced this 
effect  [220] . Positive results of smaller studies using PHMB, 
mostly without long-term follow-up  [221] , have recently 
only been partially confirmed by larger, systematic studies 
( Table 10 ). Therefore, further RCTs are needed to clarify 
the role of PHMB in NPWTi. Further experiments in in-
fected pig wounds showed a significant reduction of bio-
burden after 48 h using a combination of NPWT and a 
dressing containing silver ions, as well as with cyclic instil-
lation of OCT (for 3 min every 4 h) and NPWTi compared 
to NPWT alone  [222] . In an exemplary case of a patient 
with a high-risk of skin graft failure due to comorbidities, 
the application of NPWTi with OCT led to uneventful 
healing. A second patient developed skin graft necrosis af-
ter the use of PVP-I; regrafting and a change to NPWTi 
with OCT was followed by uncomplicated healing  [223] . 
In both studies, a solution with 0.05% OCT without the ad-
dition of PE was used. Grade-4 gluteal pressure ulcers 4 
( n = 3) treated by NPWTi with OCT healed completely 
within 4 weeks  [224] . Representative studies (e.g., RCTs, 
larger prospective cohort studies) using NPWTi in combi-
nation with OCT are still lacking. The single study of 
NPWTi with NaOCl has merely indicative character ( Ta-
ble  11 ). Due to aseptic necrosis after the application of 
OCT into tissue, Willy et al.  [225] recommend a limited 
use of NPWT with OCT in case of deeper injuries.
 Acetic Acid 
 Generally speaking, an acidic wound environment supports 
control of infection, toxicity of bacterial metabolites, protease ac-
tivity inhibition, release of oxygen, and epithelialization as well 
as angiogenesis  [226] .
 In vitro and Animal Study Results 
 AA is, just like NaOCl/HOCl, a physiologically active 
substance. It was already noticed in 1916 that coloniza-
tion with  P. aeruginosa was only rarely observed in an 
acidic wound environment  [227] . When comparing dif-
ferent acids, AA showed a superior effect  [227, 228] ; at pH 
3, the antimicrobial effect was 10–100 times stronger 
compared to other acids. It is assumed that undissociated 
AA is able to penetrate the cell better due to improved 
lipid solubility. The MIC (agar dilution test, 72 h) was ob-
served to be 9% for  S. aureus , 8–10% for MRSA, 4% for  E. 
coli , 3% for  Salmonella typhi , and 2% for  P. aeruginosa 
 [229, 230] . In the dilution test (18 h) MIC varied between 
0.16 and 0.31%. Biofilms were eliminated by 0.31% AA in 
3 h  [231] . The following reduction rates were obtained in 
suspension tests with concentrations that were nontoxic 
for fibroblasts after 15 min: 0.005% NaOCl >8 log versus 
 S. aureus , P. aeruginosa , E. coli ,  Enterococcus spp., and 
 Bacteroides fragilis . 0.0025% AA was only effective against 
 S. aureus with <1 log 10 and  P. aeruginosa with 3 log 10 , 
0.001% PVP-I was effective only against  S. aureus with 
3 log 10 and  P. aeruginosa with <1 log 10 , while 0.003% 
H 2 O 2 was ineffective against all test organisms  [232] . In 
the quantitative suspension test, 1% AA eliminated  Pro-
teus vulgaris , P. aeruginosa , Acinetobacter baumannii , 
and β-hemolytic streptococci within 5 min, and  S. aureus 
and  S. epidermidis within 10 min. 0.04% PHMB, OCT/
PE, and PVP-I 11% also only needed 5 min to accomplish 
this, but 10 min were necessary against  P. vulgaris  [233] . 
In cell culture with fibroblasts, 1% PVP-I (IC 100 ), 3% 
H 2 O 2 (IC 100 ), 0.5% NaOCl (IC 100 ), and 0.25% AA (IC 25 ) 
proved to be cytotoxic  [47] . In an animal model with 
aseptic wounds down to the fascia, epithelialization was 
only delayed significantly up to the 8th day with the test-
ed concentrations, and H 2 O 2 proved completely ineffec-
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 Table 9.  Summary of clinical study findings for PVP-I or PVP-I-L and C-I
Type of wound Comparison Result Study design Sample size, 
n
Year
VLU C-I vs. standard treatment Improved wound healing and lower 
costs with C-I 
Review 4 RCTs 2016 [312]
Pressure ulcers 
(infected and 
noninfected)
PVP-I and C-I vs. 
nonantimicrobial treatment, 
lysozyme ointment, crystal 
violet, PHMB, silver 
sulfadiazine
Little evidence for improved wound 
healing in nonantimicrobial wound 
treatment interventions and 
noninfected wounds as compared 
to PVP-I
Cochrane 
review
12 RCTs 2016 [313]
VLU PVP-I vs. hydrocolloid 
dressings
No observable differences Cochrane 
review
6 RCTs 2014 [314]
Infected wounds PVP-I vs. silver foam dressing Significantly faster wound size 
reduction with silver
RCT 35/35 2014 [315]
Chronic wounds PVP-I vs. medical honey Improved results with medical 
honey in terms of wound size 
reduction, comfort, and pain 
during dressing change
RCT 20/22 2014 [174]
Chronic wounds PVP-I vs. C-I vs. silver dressing PVP-I: improved comfort and less 
pain during dressing change, lowest 
costs
Cohort study 20 2013 [175]
Chronic wounds, 
burns, pressure 
ulcer
29 RCTs comparing efficacy 
of PVP-I and C-I with 
hydrocolloids, silver, zinc, 
dextranomer, and NaCl 
solution
In some RCTs advantage of PVP-I 
over nonantiseptics and other 
antiseptics, particularly for burns; 
otherwise no benefit of one method 
against the other
Review 29 RCTs 2010 [172]
 Table 10.  Summary of clinical findings for wound antiseptics
Criteria NaOCl/HOCl OCT PHMB PVP-I
Antimicrobial efficacy Yes Yes Yes Yes
Improvement of wound 
healing
Yes No inhibition Yes Partly inhibition
Peritoneal lavage in septic peritonitis Possible Contraindicated Contraindicated Contraindicated
Applicability of CNS tissue Possible Contraindicated Contraindicated Toxic [316]
Applicability on cartilage Possible Contraindicated Only at <0.005% Yes 
Superior to 
Ag+ Tendentially better Significantly better Significantly better Tendentially better
PVP-I Significantly better Tendentially better Significantly better –
CHD No studies No studies Significantly better No studies
Prevention of SSI Possible No studies Effective Tendentially better
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tive. The tear resistance of wounds was not impaired.  S. 
aureus was eliminated by noncytotoxic concentrations of 
PVP-I (0.001%) and NaOCl (0.005%). For H 2 O 2 and AA, 
however, the noncytotoxic concentrations proved inef-
fective  [47] . A 0.15% AA solution stimulated wound heal-
ing [161]. For experimental wounds on rats and human 
split-skin removal sites, wound healing was generally ac-
celerated with 0.25% AA, 11% PVP-I, and 3% H 2 O 2 , but 
after detachment of the scab, H 2 O 2 caused blisters and 
ulcerations in contrast to AA and PVP-I  [234] .
 Adverse Effects 
 On wounds, concentrations >2% caused pain  [230] 
and >5% caused a burning sensation  [235] . 
 Clinical Studies 
 The concentrations effective for eliminating  P. aerugi-
nosa on small ulcerations and burns varied between 1 and 
5%, and eradication occurred after 2–16 days  [230, 235–
239] . In burn patients,  P .  aeruginosa was eliminated after 
2–17 days following a daily bath in 0.5% AA for 22–45 
min  [235] . After cleaning the wound with sterile NaCl 
solution, a compress drenched in 3% AA was changed 
daily and fixated via dressing. After 2–12 days,  P. aerugi-
nosa was eliminated  [236] . Using NPWTi with 1% AA 
( n = 3; instillation of 30 mL twice daily for 3 weeks, no con-
trol), the number of pathogens (MRSA, Gram-negative) 
was significantly reduced ( n = 2) or eliminated; this was 
associated with improved healing and a shift from highly 
basic pH to a weak basic or neutral pH  [240] ( Table 12 ).
 Contraindications 
 No contraindications are known.
 Cold Atmospheric Plasma 
 Cold atmospheric plasma (CAP) is included in this 
analysis because it mainly consists of reactive-oxygen 
species (ROS) and nitrogen species (NO), and thus has 
highly antiseptic properties. It significantly surpasses 
PVP-I and PHMB in efficacy  [241] . Against biofilms, it 
performs almost as well as PHMB and CHD  [242] . On the 
skin, the efficacy is only slightly lower than that of OCT 
 [243] . The plasma’s idiosyncrasy is that biochemically ac-
tive compounds are created instrumentally and display 
other qualities in addition to the antimicrobial effect. As 
with the introduction of portable laser technology and as-
sociated innovations, the development of mobile devices 
 [244, 253] allows multiple local plasma applications. At 
 Table 11.  Summary of clinical study findings for NPWTi
Type of wound Comparison Result Study design Sample size, 
n
Year
Infected wounds NPWTi PHMB/PVP-I 
vs. NPWTi with NaCl 
solution
No difference in the number of 
surgical procedures, length of stay, 
wound healing rate; with NaCl: 
significant reduction in time to final 
surgical treatment
RCT 100/83 2015
[317]
Chronic wounds NPWT vs. NPWTi 
PHMB + PVP-I
PHMB: significantly fewer dressing 
changes, shorter hospitalization, 
shorter surgical procedure times, 
faster wound closure, faster bacterial 
elimination
Retrospective 
case-control study
74/68 2014
[221]
Chronic wounds PHMB-soaked gauze vs. 
NPWTi with PHMB-
impregnated gauze
NPWTi: significantly better wound 
healing, shorter treatment time, 
elimination of bioburden
RCT 25/25 2013
[318]
Chronic wounds NPWT vs. NPWTi with 
NaOCl 0.125%
Significant reduction of bacterial 
load per gram of tissue compared to 
NPWT alone
Prospective 
randomized 
sequential study
8/8 2012
[319]
Osteomyelitis NPWTi with PHMB vs. 
historic control
PHMB: significantly faster reduction 
of infection, shorter hospitalization, 
fewer surgical interventions
Retrospective 
case-control study
30/94 2009
[320]
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the moment, these are focused around the therapy of 
chronic wounds  [245–249] , tumors  [250] , and eliminat-
ing biofilm on implants  [251–253] . 
 The biochemically active compounds (electrons, ions, excited 
atoms and molecules such as ROS and NO, atoms or molecules 
with unpaired electrons, photons or electromagnetic fields) are 
created during plasma generation through interaction with mole-
cules from the surrounding air and/or medium and body fluids or 
tissue. 
 The hypothesis  [254, 255] for the analysis of plasma 
used in wound healing is founded on the following as-
sumptions:
 – Every healing process requires energy 
 – The center of chronic wounds is hypoxic and hypo-
thermic, and an energy deficit will inhibit wound heal-
ing 
 – A higher tissue temperature (>38  °  C), elevated oxygen 
partial pressure (to provide aerobic energy), and in-
creased blood circulation (for the transport of energy-
rich substrates and metabolites) support wound heal-
ing  
 – Damaged cells in the wound area inhibit wound heal-
ing 
 – Critical colonization/biofilm formation or infection 
will block wound healing 
 – Endotoxin absorption or binding facilitate wound 
healing  
 – The existence of induced electrical flow and ion distri-
bution based on electrical signals are important for cell 
migration and distribution at the edge of the wound  
 In vitro and Animal Experiment Findings 
 The microbicidal effect of CAP was observed in vitro 
 [256–261] on skin and chronic wounds, and exceeds the 
effectiveness of CHD, PVP-I, and PHMB. In a 3D epider-
mis model, CAP displayed dose- and time-dependent 
compatibility  [256] ;  P. aeruginosa was inactivated with-
out destroying the structure of the epidermis. Cell prolif-
eration is supported in cell culture  [247] . For degree-IIa 
superficial dermal wounds and degree-III wounds with 
complete loss of skin on pigs, the wound healing duration 
did not differ from the control, and no increase in inflam-
mation reactions or cell atypia was found. An increased 
IL-6 and IL-8 release was induced for keratinocytes and 
mononuclear cells. The support of circulation and angio-
genesis was also observed  [262] . On the chorioallantoic 
membrane, a heightened leukocyte-endothelium interac-
tion with an increased fraction of rolling leukocytes and 
leukocytes solidly attached to the vascular endothelium 
(as a precursor to diapedesis into the surrounding tissue) 
was documented  [247, 263] . This may signal an increase 
in inflammatory and immunological reaction due to the 
stimulus caused by CAP. No mutagenic potency was doc-
umented for the plasma source used in these experiments 
 [264] .
 Clinical Results 
 The healing of chronic wounds for small animals 
(treatment duration 4–5 s/cm 2 of wound surface, twice a 
week) supports the hypothesis that the healing process 
starts with an intermediate acute inflammation. Because 
 Table 12.  Summary of clinical study findings for AA
Type of wound Comparison Result Study design Sample size, 
n
Year
Chronic wounds 1% AA vs. NaCl AA: P. aeruginosa reduced significantly 
faster (day 7)
RCT 16/16 2016
[230]
VLU 0.25% AA vs. 0.25% 
chloramine
AA: 15-min wet-to-moist gauze 
application yielded a significant 
reduction of total colony count and 
S. aureus; P. aeruginosa, Proteus spp., 
S. epidermidis, and S. haemolyticus 
group G with both test compounds was 
not reduced significantly
Quasi-experimental 
intervention study
45 1995 
[321]
Burns or superficial 
wounds
5% AA vs. CHD or 
hypochlorite
AA: elimination of P. aeruginosa within 
2 – 7 days in 8/10 patients and 1/10 after 
4 days in the control group
RCT 10/0 1968 
[238]
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CAP exhibits no remanent effect, OCT or PHMB was ap-
plied after each plasma treatment. The wound dressing 
was renewed daily and the wound was cleaned with the 
initially used antiseptic  [265] . Regarding chronic ulcers 
in humans, however, no corresponding results were 
achieved, probably since CAP was not used in conjunc-
tion with remanently effective antiseptics  [266] . There 
was no evidence of adverse reactions on human skin or 
chronic wounds. The penetration depth never exceeded 
60 μm  [247] .
 Caveats 
 Because of oxidative stress, the resulting formation of 
ROS and NO, and an increase in the inflammation cas-
cade in burn wounds  [267] , application of CAP on burns 
should not be started before its safety has been confirmed 
in animal-based experimental studies. 
 Contraindications 
 No contraindications are known.
 Conclusion and Practical Recommendations 
 Wound antiseptics are indicated for the treatment of 
critically colonized and infected chronic wounds, to pre-
vent the development of infection in acute wounds with 
increased risk of infection, such as bites, stabs/punctures, 
or burns, for decolonization of wounds colonized with 
MDROs, and for the prevention of SSI. In case of a longer 
surgery duration (about  ≥ 1 h), a single rinsing of the sur-
gical area appears to be reasonable  [225] , since more than 
50% of all surgical gloves are contaminated during this 
time  [268] .
 Due to the paucity of clinical studies, the selection of 
wound antiseptics is based on both preclinical and clini-
cal studies of nonuniform research quality and design. 
After assessing characteristics and the available research, 
it can be summarized that for critically colonized and in-
fected chronic wounds as well as for burns, PHMB is the 
antiseptic of choice. For bites, stabs/punctures, and gun-
shot wounds, PVP-I is the first agent of choice, while 
PHMB and hypochlorite are superior to PVP-I for the 
treatment of contaminated acute and chronic wounds. 
For the decolonization of MDRO-colonized or infected 
wounds, the combination of OCT/PE is preferred. For 
peritoneal lavage or rinsing of other cavities with a lack of 
drainage potential as well as when the risk of CNS expo-
sure exists, hypochlorite is the antiseptic of choice ( Ta-
ble 13 ).
 Addendum 
 This consensus document was reviewed and formally approved 
by the respective boards of the following scientific societies: Anti-
septics Working Group of the International Society of Chemo-
therapy for Infection and Cancer (ISC), German Society for Hos-
pital Hygiene (Deutsche Gesellschaft für Krankenhaushygiene, 
DGKH), the Chronic Wound Initiative (Initiative Chronische 
Wunden e.V., ICW), Austrian Society for Infection Control (Ös-
terreichische Gesellschaft für Krankenhaushygiene, ÖGKH), Or-
ganization of all German-speaking Societies and Groups in Wound 
Management (Dachorganisation deutschsprachiger Vereine und 
Gruppen im Bereich Wundmanagement, Wund-D.A.CH).
 Table 13.  Orientating recommendation for the indication-based selection of wound antiseptics
Indication  Antiseptic compound
1st  choice 2nd choice
Critically colonized wounds, wounds at risk of infection PHMB OCT, hypochlorite, silver
Burns PHMB OCT, hypochlorite
Bite, stab, and gunshot wounds PVP-I Hypochlorite
MDRO-colonized or infected wounds OCT/PE OCT, PHMB, silver 
Prevention of SSI PHMB OCT/PE
Decontamination of acute and chronic wounds Hypochlorite, PHMB –
Peritoneal lavage Hypochlorite –
Risk of CNS tissue exposure Hypochlorite PVP-I
Wounds with lack of drainage Hypochlorite PHMB
 Kramer/Dissemond/Kim/Willy/Mayer/
Papke/Tuchmann/Assadian
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